SCHEMBL8280540

SCHEMBL8280540

CCc1cc(-c2ccccc2)cc(Cl)c1C1C(=O)N2CCOCCN2C1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.41
CYP2D6 P10635 2/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
PKM P14618 1/20 0.37
MEN1 O00255 1/20 0.36
POLB P06746 1/20 0.36
GAA P10253 1/20 0.36
KMT2A Q03164 1/20 0.36
KDM4E B2RXH2 2/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
MOK Q9UQ07 1/20 0.35
CYP2A13 Q16696 1/20 0.35
PRKDC P78527 3/20 0.34
OPRK1 P41145 1/20 0.34
UTS2R Q9UKP6 1/20 0.34
MAPT P10636 1/20 0.34
HTT P42858 1/20 0.34
GRIN2B Q13224 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pinoxaden Dione SCHEMBL64757 0.74 TSHR (0.39) MEN1POLBGAAKMT2AKDM4E
SCHEMBL6488155 0.68 KMT2A (0.34) CYP3A4CYP2C19PKMMEN1GAA
SCHEMBL6113843 0.66 CNR2 (0.46) PKMMEN1POLBGAAKMT2A
SCHEMBL22661242 0.65 CNR2 (0.32) MEN1KMT2AKDM4EMAPT
SCHEMBL11989372 0.65 PRKDC (0.41) MEN1KMT2AKDM4EALDH1A1LMNA
SCHEMBL12022374 0.64 PRKDC (0.38) GAAKDM4EALDH1A1LMNAPRKDC
SCHEMBL4459107 0.61 HPGD (0.31) KMT2AKDM4EALDH1A1HTT
SCHEMBL455298 0.61 ESR2 (0.47) CYP3A4CYP2D6CYP2C9CYP2C19MAPT
SCHEMBL458111 0.61 ESR2 (0.52) MAPT
SCHEMBL7615550 0.60 POLB (0.44) CYP3A4POLBALDH1A1MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130040935-A1 CYCLIC KETO-ENOLS FOR THERAPY BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-02-14 US disclosed
US-20130040935-A1 CYCLIC KETO-ENOLS FOR THERAPY BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-02-14 US disclosed
US-20120129833-A1 CYCLIC KETOENOLS FOR THERAPY BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-05-24 US disclosed
US-20120129833-A1 CYCLIC KETOENOLS FOR THERAPY BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130040935-A1 CYCLIC KETO-ENOLS FOR THERAPY AKR1B1, AKR1C3, AKR1A1 CYP3A4 520/4885CYP2D6 486/4885CYP2C9 798/4885
US-20120129833-A1 CYCLIC KETOENOLS FOR THERAPY CYP46A1, LIPC, CYP27A1 CYP3A4 164/4885CYP2D6 322/4885CYP2C9 197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.